Leading labware equipment manufacturer that has well-known companies such as Dr. Reddy’s, Dr. Lal Pathlabs, Metropolis Healthcare, and many more as its long-term customers jumped 16 percent following the acquisition of a German company to expand its operations.
At 1:23 p.m. the shares of Tarsons Products Limited were trading at Rs. 569, up 17 percent from its previous day’s close price of Rs. 487.30 and its market capitalization is Rs. 3,035 Crores.
Tarsons Products Limited and Tarsons Life Science Pte Limited have entered into a Share Purchase & Transfer Agreement with Nerbe R&D GmbH and Nerbe plus GmbH & Co. KG to acquire 100 percent stake in it for approximately 10-15 million Euros.
The Target Entities are engaged in the business of distribution of medical and laboratory disposables in Germany. Upon completion of the acquisition, the target companies will become step-down subsidiaries of Tarsons Products.
Tarsons Products Limited is a labware company engaged in the designing, manufacturing, development, and marketing of consumables, reusables, and others used in laboratories across research organizations, academia institutes, pharmaceutical companies, CROs, diagnostic companies, and hospitals. It has a market share of 25 percent with a Diversified product portfolio with 1,700+ SKUs across 300 product segments.
It has a strong customer base with well-known players like Dr. Reddy’s, Enzene Biosciences, Syngene International, Dr. Lal Pathlabs, Metropolis Healthcare, and many more.
As of Q2FY24, it generated 56 percent of its revenue from Consumables like Centrifuge ware, Petri dishes, and others, 39 percent from Resuables, and 5 percent from others. It generated 65 Percent of its revenue from the domestic markets and 35 percent from exports
The company’s revenue from operations declined 5.83 percent from Rs. 300.79 Crores in FY22 to Rs. 283.25 Crores in FY23, accompanied by profits of Rs. 100.66 Crores to Rs. 80.71 Crores.
Written by: Bharath K.S
